Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

#4498

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Aim(s): To evaluate the symptoms prevalence, intensity and their relation to quality of life in patients receiving PRRT.

Materials and methods: A total of 320 patients (age range 36-79) treated with 4 cycles of 7.4 GBq of Lu177-DOTATATE completed EORTC QLQ-GINET21 questionnaires before the first session of administration and all 3 succeeding treatments. The questionnaire comprised 17 items organised into five categories: endocrine symptoms (ED), GI symptoms (GI), treatment-related symptoms (TR), social functioning (SF), disease-related worries (DRW) and overall score (S). Results analysed according to change in overall score and change in category score.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,